Angela Kokinakos
Psychiatric/Mental Health · Everett, WANPI 1336786920
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,910, more than ten times the $284 reported in 2022. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $49.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$1K
- Neurocrine Biosciences, Inc.$883
- Otsuka America Pharmaceutical, Inc.$857
- E.r. Squibb & Sons, L.L.C.$696
- plus $2K from 6 others
What the payments were for
- Food & beverage$8,47799%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $1,604 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $1,326 |
| Axsome Therapeutics, Inc. | 16 | $1,208 |
| Neurocrine Biosciences, Inc. | 16 | $883 |
| Otsuka America Pharmaceutical, Inc. | 30 | $857 |
| E.r. Squibb & Sons, L.L.C. | 13 | $696 |
| Alkermes, Inc. | 14 | $625 |
| Johnson & Johnson | 10 | $396 |
| Teva Pharmaceuticals USA, Inc. | 4 | $321 |
| Vanda Pharmaceuticals Inc. | 3 | $304 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $258 |
| Supernus Pharmaceuticals, Inc. | 5 | $101 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$936
- VRAYLAR$884
- Auvelity$491
- CAPLYTA$486
- INGREZZA$454
- COBENFY$347
- REXULTI$258
- Fanapt$249
- ABILIFY MAINTENA$242
- ABILIFY ASIMTUFII$242
- ARISTADA INITIO$120
- INVEGA SUSTENNA$117
- LYBALVI$114
- UZEDY$104
How this compares
$8,579 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 55 | $172,114 |
| AustedoDeutetrabenazine | 14 | $94,208 |
| CaplytaLumateperone Tosylate | 44 | $70,362 |
| VraylarCariprazine Hcl | 49 | $68,465 |
| TrintellixVortioxetine Hydrobromide | 24 | $11,871 |
| BelsomraSuvorexant | 17 | $7,618 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,213 |
| Paliperidone ErPaliperidone | 58 | $6,176 |
| Divalproex Sodium ErDivalproex Sodium | 134 | $5,735 |
| Lamotrigine ErLamotrigine | 20 | $3,818 |
| Lurasidone Hcl | 42 | $3,352 |
| Atomoxetine Hcl | 37 | $3,309 |
| Prazosin Hcl | 156 | $3,163 |
| Duloxetine Hcl | 59 | $3,051 |
| Clozapine | 63 | $2,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $396 | $172,11455 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $321 | $94,20814 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,326 | $70,36244 claims |
| AbbVieVraylar | $1,604 | $68,46549 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 931 psychiatric/mental health providers in Washington.
Other psychiatric/mental health in Everett
- Hyesoon ChoiEverett$8K
- Sandra CarrierEverett$7K
- Jana RobisonEverett$5K
- Laura PerezEverett$5K
- Isabel Zaragoza-SanchezEverett$4K
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Dawn MasonSpokane$25K
- Jennifer WilsonYakima$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.